LFG
SPRY icon

Larson Financial Group’s ARS Pharmaceuticals SPRY Stock Holding History

Larson Financial Group’s Portfolio SPRY Stock Details SPRY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$2.06K Buy
256
+173
+208% +$1.66K ﹤0.01% 2956
2025
Q4 		$967 Buy
83
+79
+1,975% +$768 ﹤0.01% 2967
2025
Q3 		$40 Sell
4
-28
-88% -$402 ﹤0.01% 3365
2025
Q2 		$558 Buy
+32
New +$462 ﹤0.01% 2830

Other funds holding SPRY

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $915M AUM 209.71% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Larson Financial Group's SPRY Position: Q1 2026 in Review

Larson Financial Group increased its ARS Pharmaceuticals (SPRY) stake by 208% in Q1 2026, buying an estimated $1.66K and bringing the position to 256 shares worth $2.06K. The position accounts for ﹤0.01% of the portfolio, ranked #2956.

Larson Financial Group first reported a position in SPRY in Q2 2025 and has held it in 4 quarters since. 202 funds tracked by Wall St. Rank hold SPRY as of Q1 2026.

  • Larson Financial Group held 256 shares of ARS Pharmaceuticals worth $2.06K as of Q1 2026.
  • Larson Financial Group bought 173 ARS Pharmaceuticals shares in Q1 2026, an estimated $1.66K.
  • ARS Pharmaceuticals made up ﹤0.01% of Larson Financial Group's portfolio in Q1 2026, its #2956 holding.
  • Larson Financial Group first reported a position in ARS Pharmaceuticals in Q2 2025 and has held it in 4 quarters since.
  • 202 funds tracked by Wall St. Rank held ARS Pharmaceuticals as of Q1 2026.

Based on Larson Financial Group's 13F filing for Q1 2026, filed 15 May 2026.